Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Social pharma faces: Denise Silber

In the latest instalment of social pharma faces we catch up with someone who has played a pivotal role at the interface of pharma, healthcare providers and patients – Denise Silber. We’ve been lucky enough to speak with some fantastic people operating at the forefront of digital and social media pharma engagement during…

Articles

Rare is different: why doctors are often stumped by rare dis...

In part two of the ‘Rare is different’ series Frieda Hernandez explores how pharma could partner with physicians more effectively for increased diagnoses in patients with rare disorders. There are more than 7,000 rare disorders or “orphan” diseases, each affecting fewer than 200,000 people in the U.S. In Europe, a disease is...

Articles

Global protein therapeutics market: beefing up towards futur...

As the focus of the pharma industry shifts to protein therapies Shushmul Maheshwari investigates their growth and the challenges in this space. The global pharmaceutical market is foreseeing an upcoming era of scientifically engineered proteins in the laboratory, known as ‘Therapeutic Proteins’ for usage in...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.